Ionis Pharmaceuticals, Inc.
IONS
$81.84
$0.530.65%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 966.96M | 944.05M | 717.25M | 705.14M | 803.07M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 966.96M | 944.05M | 717.25M | 705.14M | 803.07M |
| Cost of Revenue | 885.95M | 886.69M | 891.30M | 905.65M | 915.94M |
| Gross Profit | 81.01M | 57.37M | -174.05M | -200.51M | -112.88M |
| SG&A Expenses | 359.06M | 323.89M | 298.38M | 274.57M | 237.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.25B | 1.21B | 1.19B | 1.18B | 1.15B |
| Operating Income | -278.05M | -266.52M | -472.43M | -475.08M | -350.38M |
| Income Before Tax | -258.72M | -274.43M | -464.16M | -460.07M | -355.80M |
| Income Tax Expenses | -2.38M | -6.22M | -6.13M | -6.17M | 3.01M |
| Earnings from Continuing Operations | -256.34 | -268.22 | -458.03 | -453.90 | -358.81 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -256.34M | -268.22M | -458.03M | -453.90M | -358.81M |
| EBIT | -278.05M | -266.52M | -472.43M | -475.08M | -350.38M |
| EBITDA | -266.80M | -255.17M | -460.86M | -463.13M | -337.93M |
| EPS Basic | -1.61 | -1.76 | -2.99 | -3.04 | -2.44 |
| Normalized Basic EPS | -1.05 | -1.04 | -1.86 | -1.91 | -1.42 |
| EPS Diluted | -1.69 | -1.83 | -2.99 | -3.04 | -2.44 |
| Normalized Diluted EPS | -1.12 | -1.11 | -1.86 | -1.91 | -1.42 |
| Average Basic Shares Outstanding | 635.64M | 624.47M | 611.29M | 598.09M | 584.09M |
| Average Diluted Shares Outstanding | 658.83M | 647.66M | 611.29M | 598.09M | 584.09M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |